132 related articles for article (PubMed ID: 2397170)
21. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma.
Pitman SW; Frei E
Cancer Treat Rep; 1977 Jul; 61(4):695-701. PubMed ID: 18282
[TBL] [Abstract][Full Text] [Related]
22. Methotrexate concentration levels in the cerebrospinal fluid during high-dose methotrexate infusions: an unreliable prediction.
Lippens RJ; Winograd B
Pediatr Hematol Oncol; 1988; 5(2):115-24. PubMed ID: 3152957
[TBL] [Abstract][Full Text] [Related]
23. High-dose methotrexate with citrovorum factor rescue for the treatment of central nervous system tumors in children.
Rosen G; Ghavimi F; Nirenberg A; Mosende C; Mehta BM
Cancer Treat Rep; 1977 Jul; 61(4):681-90. PubMed ID: 301781
[TBL] [Abstract][Full Text] [Related]
24. Central nervous system prophylaxis with combined intravenous and intrathecal methotrexate in diffuse lymphoma of aggressive histologic type.
Perez-Soler R; Smith TL; Cabanillas F
Cancer; 1986 Mar; 57(5):971-7. PubMed ID: 3753657
[TBL] [Abstract][Full Text] [Related]
25. Statistical analysis of relation between plasma methotrexate concentration and toxicity in high-dose methotrexate therapy of childhood nonHodgkin lymphoma.
Tsurusawa M; Gosho M; Mori T; Mitsui T; Sunami S; Kobayashi R; Fukano R; Tanaka F; Fujita N; Inada H; Koh K; Takimoto T; Saito A; Fujimoto J; Nakazawa A; Horibe K;
Pediatr Blood Cancer; 2015 Feb; 62(2):279-284. PubMed ID: 25359701
[TBL] [Abstract][Full Text] [Related]
26. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95.
Woessmann W; Seidemann K; Mann G; Zimmermann M; Burkhardt B; Oschlies I; Ludwig WD; Klingebiel T; Graf N; Gruhn B; Juergens H; Niggli F; Parwaresch R; Gadner H; Riehm H; Schrappe M; Reiter A;
Blood; 2005 Feb; 105(3):948-58. PubMed ID: 15486066
[TBL] [Abstract][Full Text] [Related]
27. [Investigation on individualized adjustment of target range of high-dose methotrexate].
Hua Y; Zhao WH; Lu XT; Yang LH; Lu W
Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):203-8. PubMed ID: 19099710
[TBL] [Abstract][Full Text] [Related]
28. Disposition of intermediate-dose methotrexate in children with acute lymphocytic leukemia.
Evans WE; Stewart CF; Hutson PR; Cairnes DA; Bowman WP; Yee GC; Crom WR
Drug Intell Clin Pharm; 1982 Nov; 16(11):839-42. PubMed ID: 6959800
[TBL] [Abstract][Full Text] [Related]
29. Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection.
Bleyer WA; Dedrick RL
Cancer Treat Rep; 1977 Jul; 61(4):703-8. PubMed ID: 577895
[TBL] [Abstract][Full Text] [Related]
30. 7-Hydroxymethotrexate concentrations in serum and cerebrospinal fluid of children with acute lymphoblastic leukemia.
Borsi JD; Sagen E; Romslo I; Slørdal L; Moe PJ
Cancer Chemother Pharmacol; 1990; 27(2):164-7. PubMed ID: 2249335
[TBL] [Abstract][Full Text] [Related]
31. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study.
Mahoney DH; Shuster JJ; Nitschke R; Lauer S; Steuber CP; Camitta B
J Clin Oncol; 2000 Mar; 18(6):1285-94. PubMed ID: 10715299
[TBL] [Abstract][Full Text] [Related]
32. [Studies of methotrexate pharmacokinetics in children with neoplasms of the hematopoietic system after administration of different doses of the drug].
Wysocki M; Krzyzanowski M; Ozyński T; Pilecki O; Balcar-Boroń A; Szadujkis-Szadurski L
Acta Haematol Pol; 1992; 23(3):179-83. PubMed ID: 1492542
[TBL] [Abstract][Full Text] [Related]
33. High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics.
Slørdal L; Kolmannskog S; Moe PJ; Prytz PS; Aarbakke J
Pediatr Hematol Oncol; 1987; 4(1):33-42. PubMed ID: 3152911
[TBL] [Abstract][Full Text] [Related]
34. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia.
Wolfrom C; Hartmann R; Fengler R; Brühmüller S; Ingwersen A; Henze G
J Clin Oncol; 1993 May; 11(5):827-33. PubMed ID: 8487046
[TBL] [Abstract][Full Text] [Related]
35. Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate.
Refsum H; Wesenberg F; Ueland PM
Cancer Res; 1991 Feb; 51(3):828-35. PubMed ID: 1988122
[TBL] [Abstract][Full Text] [Related]
36. Assessment of renal function during high-dose methotrexate treatment in children with acute lymphoblastic leukemia.
Ylinen E; Jahnukainen K; Saarinen-Pihkala UM; Jahnukainen T
Pediatr Blood Cancer; 2014 Dec; 61(12):2199-202. PubMed ID: 25174822
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.
Zylber-Katz E; Gomori JM; Schwartz A; Lossos A; Bokstein F; Siegal T
Clin Pharmacol Ther; 2000 Jun; 67(6):631-41. PubMed ID: 10872645
[TBL] [Abstract][Full Text] [Related]
38. Plasma and urine levels of methotrexate and 7-hydroxymethotrexate in children with ALL during maintenance therapy with weekly oral methotrexate.
Skoglund KA; Söderhäll S; Beck O; Peterson C; Wennberg M; Hayder S; Björk O
Med Pediatr Oncol; 1994; 22(3):187-93. PubMed ID: 8272008
[TBL] [Abstract][Full Text] [Related]
39. [Effect of cranial irradiation on the blood-cerebrospinal fluid and blood-brain barrier].
Ludwig R
Klin Padiatr; 1987; 199(3):233-8. PubMed ID: 3476804
[TBL] [Abstract][Full Text] [Related]
40. Serum Creatinine Versus Plasma Methotrexate Levels to Predict Toxicities in Children Receiving High-dose Methotrexate.
Tiwari P; Thomas MK; Pathania S; Dhawan D; Gupta YK; Vishnubhatla S; Bakhshi S
Pediatr Hematol Oncol; 2015; 32(8):576-84. PubMed ID: 26558505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]